<DOC>
	<DOCNO>NCT01103401</DOCNO>
	<brief_summary>This randomize controlled trial compare two regimen topical therapy : - tobramycin 0.3 % - dexamethasone 0.1 % ( TobraDex® , Alcon ) , one drop four times/day - combination tobramycin 0.3 % - dexamethasone 0.1 % ( TobraDex® , Alcon ) , one drop four times/day , plus Ketorolac tromethamine 0.5 % ( Acular® , Allergan ) , one drop three times/day . Patients independently assess two ophthalmologist . On day 7,14,21,28 patient evaluate - corneal edema - conjunctival hyperemia - anterior chamber ( Tyndall ) reaction . The investigator purpose evaluate benefit add non-steroid agent antibiotic/steroid combination uneventful phacoemulsification . Adopting weekly follow-up , gain insight optimal duration postoperative treatment examine whether risk factor inflammation exist .</brief_summary>
	<brief_title>Ketorolac Plus Tobramycin/Dexamethasone Versus Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery</brief_title>
	<detailed_description>Patients randomize : ) tobramycin 0.3 % - dexamethasone 0.1 % one drop qid ( TD group , n=72 , 28 day ) ii ) combination tobramycin 0.3 % - dexamethasone 0.1 % , one drop qid , plus Ketorolac tromethamine 0.5 % , one drop tid ( TD-K group , n=73 , 28 day ) . Patients undergo vitrectomy due posterior capsule rupture exclude . On day 7 , 14 , 21 , 28 , frequency inflammation-related sign [ corneal edema , conjunctival hyperemia , anterior chamber ( Tyndall ) reaction ] , well best correct visual acuity ( BCVA ) measure . On day 21 , logistic regression perform evaluate risk factor inflammation .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>phacoemulsification ( due cataract ) uneventful phacoemulsification surgery history intraocular surgery operate eye , previous episode uveitis operate eye , severe systemic disease ( heart failure NYHA stage III IV , endstage renal failure , pulmonary failure , patient receive chemotherapy ) , regular , systemic use steroid nonsteroid antiinflammatory drug last three month disruption anterior lens capsule</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>